Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Division of Pulmonology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang 10444, Korea.
Sensors (Basel). 2022 Mar 15;22(6):2264. doi: 10.3390/s22062264.
The purpose of this study was to explore the relationships between heart rate variability (HRV) and various phenotypic measures that relate to health and functional status in chronic obstructive pulmonary disease (COPD), and secondly, to demonstrate the feasibility of ascertaining HRV via a chest-worn wearable biosensor in COPD patients. HRV analysis was performed using SDNN (standard deviation of the mean of all normal R-R intervals), low frequency (LF), high frequency (HF), and LF/HF ratio. We evaluated the associations between HRV and COPD severity, class of bronchodilator therapy prescribed, and patient reported outcomes. Seventy-nine participants with COPD were enrolled. There were no differences in SDNN, HF, and LF/HF ratio according to COPD severity. The SDNN in participants treated with concurrent beta-agonists and muscarinic antagonists was lower than that in other participants after adjusting heart rate (beta coefficient -3.980, = 0.019). The SDNN was positively correlated with Veterans Specific Activity Questionnaire (VSAQ) score ( = 0.308, = 0.006) and handgrip strength ( = 0.285, = 0.011), and negatively correlated with dyspnea by modified Medical Research Council (mMRC) questionnaire ( = -0.234, = 0.039), health status by Saint George's Respiratory Questionnaire (SGRQ) ( = -0.298, = 0.008), symptoms by COPD Assessment Test (CAT) ( = -0.280, = 0.012), and BODE index ( = -0.269, = 0.020). When measured by a chest-worn wearable device, reduced HRV was observed in COPD participants receiving inhaled beta-sympathomimetic agonist and muscarinic antagonists. HRV was also correlated with various health status and performance measures.
本研究旨在探讨心率变异性(HRV)与慢性阻塞性肺疾病(COPD)中与健康和功能状态相关的各种表型指标之间的关系,其次,展示通过穿戴在胸部的可穿戴生物传感器在 COPD 患者中确定 HRV 的可行性。HRV 分析使用 SDNN(所有正常 R-R 间隔的平均值的标准差)、低频(LF)、高频(HF)和 LF/HF 比值进行。我们评估了 HRV 与 COPD 严重程度、所开支气管扩张剂治疗类别以及患者报告的结果之间的关联。共纳入 79 名 COPD 患者。根据 COPD 严重程度,SDNN、HF 和 LF/HF 比值没有差异。调整心率后,同时使用β激动剂和毒蕈碱拮抗剂治疗的患者的 SDNN 低于其他患者(β系数-3.980,p=0.019)。SDNN 与退伍军人专用活动问卷(VSAQ)评分呈正相关(r=0.308,p=0.006)和握力(r=0.285,p=0.011),与改良医学研究委员会呼吸困难问卷(mMRC)评分呈负相关(r=-0.234,p=0.039),与圣乔治呼吸问卷(SGRQ)健康状况评分呈负相关(r=-0.298,p=0.008),与 COPD 评估测试(CAT)症状评分呈负相关(r=-0.280,p=0.012),与 BODE 指数呈负相关(r=-0.269,p=0.020)。当使用穿戴在胸部的可穿戴设备测量时,接受吸入β拟交感神经激动剂和毒蕈碱拮抗剂治疗的 COPD 患者的 HRV 降低。HRV 还与各种健康状况和表现指标相关。